Drug Profile

CDI 873

Alternative Names: CDI-873

Latest Information Update: 28 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cocrystal Pharma Inc
Class Antivirals; Small molecules
Mechanism of Action Coronavirus 3C-like proteinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported COVID 2019 infections

Most Recent Events

28 Feb 2026 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (PO)
01 Jun 2022 Cocrystal Pharma and National Institute of Allergy and Infectious Diseases (NIAID) enters a Non-Clinical Evaluation Agreement (NCEA) for CDI 873 for COVID-2019 infections
27 Jan 2022 Cocrystal Pharma plans a phase I clinical trial for COVID-2019 infections, in 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com